Precision BioSciences, Inc. - Common Stock (DTIL)

Competitors to Precision BioSciences, Inc. - Common Stock (DTIL)

CRISPR Therapeutics AG 

CRISPR Therapeutics specializes in gene editing using CRISPR/Cas9 technology, which directly competes with Precision BioSciences' ARCUS technology. Both companies are targeting genetic diseases and looking to establish a foothold in the biopharmaceutical landscape. CRISPR Therapeutics has established partnerships and a pipeline that is actively progressing into clinical trials, which may give it a competitive advantage in term of market readiness and visibility.

CureVac N.V. 

CureVac N.V. focuses on developing mRNA-based therapies and vaccines, putting it in direct competition with Precision BioSciences' gene-editing technology. While Precision BioSciences utilizes its proprietary ARCUS genome-editing platform for precision therapies, CureVac leverages its expertise in mRNA technology to address a range of diseases. This sector has seen significant interest, especially in the wake of the COVID-19 pandemic, thereby intensifying competition. CureVac's established partnerships and funding support could provide it with a competitive advantage, particularly in vaccine development.

Editas Medicine, Inc. 

Editas Medicine, Inc. is a key player in the gene-editing arena, utilizing CRISPR technology to develop genome editing therapies. This puts it in direct competition with Precision BioSciences, which employs a different approach with its ARCUS technology. While both companies aim to revolutionize genomic medicine, Editas has been able to advance specific programs toward clinical trials more quickly, potentially giving them a leading edge in getting products to market. Thus, Editas may have a more prominent position in the clinical landscape currently.

Intellia Therapeutics, Inc. 

Intellia Therapeutics focuses on CRISPR/Cas9 technology similar to Editas, with aspirations to develop curative therapies for genetic diseases and cancer. Precision BioSciences competes by promoting its unique ARCUS technology, which is designed for more precise gene edits with fewer off-target effects. Intellia's strong research collaborations and its commitment to advancing multiple clinical programs may provide it with a competitive advantage in the fast-paced gene therapy sector.

Sana Biotechnology, Inc. 

Sana Biotechnology focuses on harnessing engineered cells for gene therapy and cell therapy applications. This positions it in competition with Precision BioSciences, as both aim to pioneer innovative therapies that leverage the power of genetic modification. Sana's access to substantial capital and diverse technological platforms for cell and gene therapies may enhance its competitive stance, particularly as it explores various treatment modalities.